Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Genmab A/S is a Danish biotechnology company specializing in the discovery, development, and commercialization of differentiated antibody therapeutics for the treatment of cancer and other serious diseases. The company operates within the global biopharmaceutical and oncology-focused biotechnology industries, with a primary emphasis on proprietary antibody technologies and collaborative drug development. Genmab’s revenue base is largely driven by royalties from marketed products developed with partners, milestone payments, and, increasingly, direct product sales.
Genmab was founded in 1999 and has evolved from a research-focused antibody technology platform company into a late-stage and commercial-stage biopharmaceutical company. Its strategic positioning is built on deep expertise in antibody engineering, including proprietary platforms that enable the development of next-generation antibody-based therapies. The company is best known for its role in the development of Darzalex (daratumumab), which established Genmab as a leading innovator in oncology antibodies.
Business Operations
Genmab’s operations are organized around antibody research and development, clinical development, and commercial activities. The company generates revenue through a combination of royalty income, milestone payments, collaboration revenue, and product sales, with royalties historically representing the largest and most stable revenue stream. Its core business is centered on the discovery and development of differentiated antibody therapeutics, particularly in oncology.
The company conducts research and development internally while also maintaining extensive global collaborations. Key marketed products include Darzalex and its subcutaneous formulation, developed in partnership with Janssen Biotech, a subsidiary of Johnson & Johnson. Genmab also commercializes Epkinly (epcoritamab) in certain markets through a co-commercialization arrangement with AbbVie. The company operates both independently and through strategic partnerships, retaining significant economic participation in its clinical and commercial programs.
Strategic Position & Investments
Genmab’s strategic direction focuses on expanding its oncology pipeline, increasing commercial-stage assets, and selectively internalizing commercialization capabilities. The company continues to invest heavily in clinical development programs across hematologic malignancies and solid tumors, leveraging its proprietary antibody technologies to differentiate its pipeline. A key strategic shift in recent years has been greater participation in downstream value creation, including co-commercialization and regional commercialization rights.
Major investments include internal R&D spending across multiple antibody formats and the continued expansion of its late-stage clinical portfolio. Genmab has also pursued targeted acquisitions and licensing agreements to strengthen its technology base and pipeline, including the acquisition of ProfoundBio to enhance its antibody-drug conjugate capabilities. Emerging areas of focus include bispecific antibodies, antibody-drug conjugates, and next-generation immune-oncology therapies.
Geographic Footprint
Genmab is headquartered in Copenhagen, Denmark, and operates as a globally integrated biotechnology company. Its research, development, and commercial activities span Europe, North America, and parts of Asia-Pacific, reflecting the global nature of its clinical trials and partnerships. The company maintains significant operations in Denmark, the United States, and the Netherlands, which together support discovery research, clinical development, regulatory affairs, and commercial execution.
Through its partnerships and licensing arrangements, Genmab’s products reach patients across North America, Europe, Asia, and other international markets. While Genmab does not operate large-scale manufacturing facilities independently, it exerts global influence through its intellectual property, clinical programs, and commercial collaborations with multinational pharmaceutical companies.
Leadership & Governance
Genmab is led by an experienced executive team with deep expertise in biotechnology research, drug development, and global commercialization. The company’s leadership emphasizes scientific excellence, disciplined capital allocation, and long-term value creation through innovation and partnerships. Governance practices are aligned with Danish and international standards for publicly listed life sciences companies.
Key members of the leadership team include:
- Jan van de Winkel – President & Chief Executive Officer
- Hans Herløv Mikkelsen – Chief Financial Officer
- Thomas Baumann – Chief Medical Officer
- Palle Brogaard – Executive Vice President & Chief Commercial Officer
- Cecilie Bendtsen – Executive Vice President & Chief Development Officer